Core Viewpoint - Microchip Biotech (688321.SH) plans to repurchase shares worth between 10 million to 15 million yuan at a price not exceeding 47.46 yuan per share, intended for employee stock ownership plans or equity incentives [1] Summary by Relevant Categories - **Share Repurchase Plan** - The company intends to repurchase shares valued between 10 million to 15 million yuan [1] - The maximum repurchase price is set at 47.46 yuan per share [1] - **Purpose of Repurchase** - The repurchased shares will be used for employee stock ownership plans or equity incentives [1]

Core Viewpoint - Microchip Biotech (688321.SH) plans to repurchase shares worth between 10 million to 15 million yuan, with a maximum repurchase price of 47.46 yuan per share, intended for employee stock ownership plans or equity incentives [1] Summary by Category - **Company Actions** - The company intends to repurchase shares valued at 10 million to 15 million yuan [1] - The maximum price for the repurchase is set at 47.46 yuan per share [1] - **Purpose of Repurchase** - The repurchased shares will be used for employee stock ownership plans or equity incentives [1]

微芯生物10月31日公告，拟以集中竞价交易方式回购公司股份，回购总金额1000.00万元~1500.00万 元，回购价格不超过47.46元/股。回购股份将用于员工持股计划或者股权激励。回购期限为自董事会审 议通过回购股份方案之日起12个月内。 ...

微芯生物公告称，公司计划以不低于1000万元且不超过1500万元的自有资金及股票回购专项贷款，通过 集中竞价交易方式回购部分A股股份，回购价格不超过47.46元/股。回购的股份将用于员工持股计划或 股权激励。董事会已通过该回购方案，无需提交股东大会审议。公司董事长XIANPINGLU提议回购， 并承诺推动公司尽快召开董事会审议回购股份事项。回购期限为自董事会审议通过之日起12个月内。 (本文来自第一财经) ...

Group 1 - The company Microchip Biotech (SH 688321) announced on October 31 that its 17th meeting of the third board of directors for 2025 was held on October 30, 2025, combining in-person and communication methods [1] - The company reported that for the year 2024, its revenue composition is 97.96% from the pharmaceutical manufacturing industry and 2.04% from other businesses [1] - As of the report, Microchip Biotech has a market capitalization of 12.6 billion yuan [1]

Core Viewpoint - Microchip Biotech (688321.SH) plans to repurchase A-shares using self-owned funds and a special loan, with a total amount between 10 million and 15 million yuan, at a price not exceeding 47.46 yuan per share [1] Group 1 - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] - The board of directors has approved the repurchase plan without needing to submit it for shareholder meeting approval [1] - The repurchase period is set for 12 months from the date of board approval [1]

Group 1 - The company, Microchip Biotech (688321.SH), announced a share repurchase plan aimed at employee stock ownership or equity incentives [1] - The total amount for the share repurchase will be no less than RMB 10 million and no more than RMB 15 million [1] - The maximum repurchase price is set at RMB 47.46 per share [1]

微芯生物公告称，公司拟以集中竞价交易方式回购股份，金额不低于1000万元且不超过1500万元，资金 源于自有资金及专项贷款。回购价不超47.46元/股，数量为21.07万股至31.6万股，占总股本0.05% - 0.08%，用于员工持股计划或股权激励，期限自董事会审议通过起12个月内。截至公告披露日，除持股 5%以上股东博奥生物正履行减持计划外，其余相关方暂无明确增减持计划。本次回购存在价格、用 途、重大事项及监管政策等风险。 ...

Core Viewpoint - Shenzhen MicuRx Pharmaceuticals, Inc. reported a significant revenue growth of 40.12% year-on-year for the first three quarters of 2025, driven by increased sales of its products, particularly Sidaracizumab and Siglec-1 [1] Financial Performance - The company achieved a total revenue of 674 million yuan in the first three quarters [1] - Sales revenue for Sidaracizumab increased by 18.76% year-on-year [1] - Sales revenue for Siglec-1 surged by 136.13% year-on-year [1] Product Development and Strategy - MicuRx Pharmaceuticals has developed a global strategy based on early research in China, leveraging a team of top scientists with extensive experience in relevant fields [1] - The company employs an integrated technology platform that combines AI-assisted design and chemical genomics, facilitating the entire process from basic research to clinical translation [1] - As of June 30, the company has two innovative drugs with multiple indications globally marketed, focusing on five major areas: malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments [1]

Core Points - The Shanghai Composite Index closed at 3961.62 points, above the six-month moving average, with a decline of 0.63% [1] - The total trading volume of A-shares reached 157.92 billion yuan [1] - A total of 259 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3961.62 points, indicating a slight decline of 0.63% [1] - The total trading volume for A-shares today is reported at 157.91 billion yuan [1] Stocks Surpassing Six-Month Moving Average - 259 A-shares have broken through the six-month moving average, with the highest deviation rates observed in stocks such as: - Yatong Precision Engineering (8.20%) - Excellent New Energy (7.57%) - Deyuan Pharmaceutical (7.38%) [1] - Other stocks with smaller deviation rates include: - New Hope - Shanghai Phoenix - Angli Education, which have just crossed the six-month line [1] Notable Stocks and Their Metrics - Top stocks with significant price changes and their metrics include: - Yatong Precision Engineering: +9.76%, turnover rate 31.45%, six-month line 23.27 yuan, latest price 25.18 yuan, deviation rate 8.20% [1] - Excellent New Energy: +9.90%, turnover rate 2.44%, six-month line 45.62 yuan, latest price 49.07 yuan, deviation rate 7.57% [1] - Deyuan Pharmaceutical: +11.83%, turnover rate 8.02%, six-month line 38.03 yuan, latest price 40.84 yuan, deviation rate 7.38% [1]